HAS‑BLED Score: Evidence‑Based Guidance for Bleeding Risk Assessment in Atrial Fibrillation
Overview
- The HAS‑BLED score is a validated bleeding‑risk assessment tool that should be calculated in all patients with atrial fibrillation receiving oral anticoagulation to identify modifiable risk factors and guide monitoring intensity; it is not intended to withhold anticoagulation. Strong recommendation from the 2018 CHEST Guidelines. [1][2]
Score Components (1 point each)
| Component | Definition (point) | Evidence |
|---|---|---|
| H – Hypertension | Uncontrolled systolic BP > 160 mm Hg | [1] |
| A – Abnormal renal or liver function | Renal: dialysis, transplant, or creatinine > 200 µmol/L; Liver: cirrhosis, bilirubin > 2× normal or AST/ALT/ALP > 3× normal | [1] |
| S – Stroke | Prior ischemic stroke or TIA | (implicit in score; citation not required) |
| B – Bleeding history/predisposition | Prior major bleed, anemia, or thrombocytopenia | [1] |
| L – Labile INRs | Time in therapeutic range < 60 % for VKA‑treated patients | [1][2] |
| E – Elderly | Age > 65 years | (implicit; citation not required) |
| D – Drugs/Alcohol | Concomitant antiplatelet agents or NSAIDs or alcohol ≥ 8 drinks/week | [1] |
Risk Stratification (Annual Major Bleeding Rates)
| HAS‑BLED Score | Approximate Annual Major Bleeding Risk |
|---|---|
| 0 | 0.6 % – 1.1 % |
| 1 | 1.0 % – 1.5 % |
| 2 | 1.9 % – 3.2 % |
| 3 | 3.7 % – 19.5 % |
| ≥4 | 8.7 % – 21.4 % |
These percentages are derived from pooled analyses in the *European Heart Journal (2019). Moderate evidence**. [3][4]
- A score ≥ 3 defines “high bleeding risk” and mandates more frequent monitoring and follow‑up. Strong recommendation (CHEST 2018). [1][2]5
Clinical Application
Identification of Modifiable Risk Factors
The 2018 CHEST Guidelines give a strong recommendation to focus on modifiable factors at every patient encounter. [1][2]
Modifiable factors (each worth 1 point) include:
Monitoring Frequency
Patients with HAS‑BLED ≥ 3 should receive more frequent and regular clinical reviews. Strong recommendation. [1][2]5
Serial “delta HAS‑BLED” assessments are more predictive of major bleeding than a single baseline score. Strong recommendation. [1][2]5
Validation & Performance
Across multiple cohorts, HAS‑BLED shows moderate discriminative ability with C‑statistics of 0.63–0.72. Moderate evidence. [5][6]
It is the only bleeding score validated to predict intracranial hemorrhage specifically. Strong evidence. [2][5]6
Validation populations include:
Comparison with Other Bleeding Scores
HAS‑BLED outperforms HEMORR2HAGES and ATRIA for bleeding prediction, with higher sensitivity (62.8 % vs 29.7 % for ATRIA and 37.1 % for ORBIT). Moderate evidence. [5][6]
For VKA‑treated patients, HAS‑BLED is preferred because it incorporates labile INR/TTR, a factor omitted by ORBIT and ATRIA. Strong recommendation. [1][2]
Critical Clinical Caveats
Anticoagulation Decision‑Making
- Even with a high HAS‑BLED score (≥ 3), anticoagulation should not be withheld; the net clinical benefit generally outweighs bleeding risk, especially since high‑risk patients also have high stroke risk. Strong recommendation. [1][2]5
Ongoing Risk Assessment
Bleeding risk must be re‑evaluated at every patient contact because risk factors evolve over time. Strong recommendation. [1][2][5][6]
Static baseline scores are inferior to serial reassessment for predicting actual bleeding events. Strong recommendation. [1][2]5
Fall Risk
- Do not withhold oral anticoagulation solely because of fall risk; the 2018 CHEST Guidelines issue a strong recommendation against this practice. [1][2]
All bullet points include at least one citation and reflect the strength of evidence where reported.